Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter's Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Market by Category 41
3.1 Market Overview by Category 41
3.2 Pharmaceutical Industry 43
3.3 Biopharmaceutical Industry 44
4 Segmentation of Asia Pacific Market by Product 45
4.1 Market Overview by Product 45
4.2 Active Pharmaceutical Ingredients (API) 47
4.2.1 Branded API Manufacturing 48
4.2.2 Generic API Manufacturing 49
4.3 Finished Dosage Formulations (FDF) 50
4.3.1 Solid Dosage 52
4.3.2 Oral Liquids 53
4.3.3 Parenteral/Injectables 54
4.3.4 Other FDFs 55
4.4 Secondary Packaging 56
5 Segmentation of Asia Pacific Market by Phase 57
5.1 Market Overview by Phase 57
5.2 Clinical Manufacturing 59
5.3 Commercial Manufacturing 60
6 Segmentation of Asia Pacific Market by Type 61
6.1 Market Overview by Type 61
6.2 Sterile Products 63
6.3 Non-Sterile Products 64
7 Segmentation of Asia Pacific Market by Therapeutic Application 65
7.1 Market Overview by Therapeutic Application 65
7.2 Infectious Diseases 67
7.3 Oncology 68
7.4 Metabolic Disorders 69
7.5 Cardiovascular Disorders 70
7.6 Central Nervous System 71
7.7 Pulmonary Disorders 72
7.8 Gastrointestinal Disorders 73
7.9 Other Therapeutic Applications 74
8 Asia-Pacific Market 2019-2030 by Country 75
8.1 Overview of Asia-Pacific Market 75
8.2 Japan 78
8.3 China 81
8.4 Australia 84
8.5 India 86
8.6 South Korea 88
8.7 Rest of APAC Region 90
9 Competitive Landscape 92
9.1 Overview of Key Vendors 92
9.2 New Product Launch, Partnership, Investment, and M&A 95
9.3 Company Profiles 96
Aenova Group 96
Baxter BioPharma Solutions 98
Boehringer Ingelheim 99
Catalent Inc. 100
Famar S.A. 101
Hospira, Inc. 102
Jubilant Life Sciences Ltd. 103
Lonza Group 104
Patheon Inc. 105
Pfizer CentreSource 106
Recipharm AB 107
Vetter Pharma International GmbH 108
10 Investing in Asia Pacific Market: Risk Assessment and Management 109
10.1 Risk Evaluation of Asia Pacific Market 109
10.2 Critical Success Factors (CSFs) 112
Related Reports and Products 115